GlassScriptPhysician profile
Manjula Kari
NPI 1720110133
$2,061.89
in general payments reported to CMS, 2019-2025
20 companies · $269 in 2025
The $269 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $119 · 2021: $216 · 2022: $332 · 2023: $318 · 2024: $475 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $515.72 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Pfizer INC. | $316.27 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $271.84 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $180.49 | 2019-2023 | Auvi-Q |
| Glaxosmithkline, LLC. | $139.53 | 2019-2024 | Bexsero, Shingrix, Rotarix |
| Sanofi Pasteur INC. | $128.76 | 2019-2024 | |
| Cranial Technologies, INC | $112.61 | 2019-2025 | Doc Band |
| Alk-Abello, INC | $65.37 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $47.57 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $41.87 | 2024 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $40.61 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $37.28 | 2024 | Relexxii |
| Biogen, INC. | $35.93 | 2022 | |
| Dermira, INC. | $24.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $19.63 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18.95 | 2021 | |
| Aytu Biopharma, INC. | $17.90 | 2024 | Karbinal |
| Metacel Pharmaceuticals LLC | $17.36 | 2023 | Ozobax |
| Mylan Pharmaceuticals INC. | $17.17 | 2019 | |
| Phadia US INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjula Kari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.